Lumexa Imaging Holdings enters the week with a fresh analyst cut pressing down on a stock that has already given back all of its post-Q1 bounce and then some.
The standout development this week is the Barclays target reduction. Andrew Mok at Barclays — who had maintained an Overweight rating through the initial Q1-driven selloff — cut his price target this morning from $15 to $9, a 40% reduction that now sits just $2 above Tuesday's close of $7. That follows a prior cut from $23 to $15 in April. The cumulative downgrade path from $23 to $9 over six weeks tells a story of a thesis under active revision, not a one-off adjustment. Raymond James still carries a Strong Buy with a $23 target, and the mean across the coverage group is $18 — more than 150% above the current price. That kind of dispersion usually reflects genuine uncertainty about the trajectory, rather than consensus conviction in either direction.
The price action since the May 13 article tells the updated story. LMRI is down 33% on the week and 28% over the past month, closing at $7.00 on Tuesday. The Q1 beat that drove short covering two weeks ago has been fully reversed. The May 12 earnings release — which triggered a 21% one-day drop and a 31% five-day decline per the ORTEX data — now looks like the dominant event shaping the tape. Tuesday's 3.4% gain is a modest countertrend move within a steep descent.
The positioning picture has shifted noticeably from two weeks ago. Short interest has drifted back up modestly, rising roughly 5% over the past week to 3.2 million shares, partially reversing the post-earnings covering that was the main story in the last note. The ORTEX short score has eased to 65.6 from its May 6 peak of 70.3, but it remains elevated — well above a neutral reading — signalling that bearish conviction has not been abandoned. Cost to borrow has climbed sharply, nearly quadrupling from around 0.85% in late April to 5.4% now. That increase in the cost to establish or maintain short positions is notable, and it coincides with availability tightening: at 142%, the lending pool still has room, but that reading has contracted meaningfully from above 300% in mid-April. The direction of travel is toward tighter borrow conditions even as short interest tries to rebuild.
Institutional ownership adds an important structural overlay. Welsh, Carson, Anderson & Stowe holds nearly 70% of shares, leaving a very thin tradeable float. With under 10% of shares distributed across all other institutional holders, daily moves in either direction can be amplified by relatively modest flows. BlackRock added 1.4 million shares as of April 30, and Brown Advisory built a fresh 1.7 million share position as of Q1 end — both suggesting some institutional buyers stepped in while the stock was falling. MFS and AllianceBernstein also added materially. Against that backdrop, the Director-level open-market purchase of 30,000 shares at $7.44 on May 14 looks modest in absolute terms but directionally consistent with the institutional accumulation theme.
The next earnings event is scheduled for June 10. With the stock down 62% year-to-date, the Street still holding mostly bullish ratings but cutting targets aggressively, and cost to borrow continuing to rise, the key question heading into that print is whether the Q1 beat represented a genuine operational turn or a one-quarter outlier — and whether the current price already reflects the answer.
See the live data behind this article on ORTEX.
Open LMRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
